Adding Third Drug Fails to Improve Outcomes in Advanced Kidney Cancer Trial

A large Phase 3 trial (LITESPARK-012) for advanced kidney cancer found that adding a third drug, either belzutifan or MK-1308A, to the standard Keytruda and Lenvima combination did not help patients live longer or keep their cancer in check longer. The results, presented at the European Society for Medical Oncology (ESMO) Congress, suggest the two-drug combination remains the most effective standard of care.